{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108983","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.052896+00:00","generated_at":"2026-05-17T13:05:38.179845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcadia Q2 net loss $4.5M on $4.5M credit loss; Zola revenue up 24%","bullets":["Total revenue $1.455M (+11% YoY); Zola coconut water sales grew 24% to $1.455M.","Net loss attributable to common $4.458M ($3.26/share) vs net income $1.061M ($0.78/share) in Q2 2024.","Recorded $4.5M credit loss on Above Food note receivable; received 2.7M shares of ABVE stock.","Eliminated $1M contingent liability via Bioseed India license termination; total YTD eliminated $2M.","Gross margins exceeded 30% for tenth consecutive quarter; SG&A fell 21% to $2.123M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108983","json":"https://secwatch.observer/filing/0000950170-25-108983.json","markdown":"https://secwatch.observer/filing/0000950170-25-108983.md","text":"https://secwatch.observer/filing/0000950170-25-108983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017025108983/0000950170-25-108983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017025108983/rkda-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:05:38.179845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}